CN119954917A - 作为疫苗的修饰的梭菌神经毒素和结合疫苗平台 - Google Patents

作为疫苗的修饰的梭菌神经毒素和结合疫苗平台 Download PDF

Info

Publication number
CN119954917A
CN119954917A CN202411849786.4A CN202411849786A CN119954917A CN 119954917 A CN119954917 A CN 119954917A CN 202411849786 A CN202411849786 A CN 202411849786A CN 119954917 A CN119954917 A CN 119954917A
Authority
CN
China
Prior art keywords
bont
toxin
amino acid
vaccine
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411849786.4A
Other languages
English (en)
Chinese (zh)
Inventor
J·T·巴比里
E·A·约翰逊
S·佩莱特
W·H·泰普
A·普莱兹佩斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical College of Wisconsin
Wisconsin Alumni Research Foundation
Original Assignee
Medical College of Wisconsin
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical College of Wisconsin, Wisconsin Alumni Research Foundation filed Critical Medical College of Wisconsin
Publication of CN119954917A publication Critical patent/CN119954917A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0015—Combination vaccines based on measles-mumps-rubella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202411849786.4A 2017-12-15 2018-12-17 作为疫苗的修饰的梭菌神经毒素和结合疫苗平台 Pending CN119954917A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762599444P 2017-12-15 2017-12-15
US62/599,444 2017-12-15
PCT/US2018/066033 WO2019118974A2 (en) 2017-12-15 2018-12-17 Modified clostridial neurotoxins as vaccines and conjugate vaccine platforms
CN201880081008.1A CN111479821B (zh) 2017-12-15 2018-12-17 作为疫苗的修饰的梭菌神经毒素和结合疫苗平台

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880081008.1A Division CN111479821B (zh) 2017-12-15 2018-12-17 作为疫苗的修饰的梭菌神经毒素和结合疫苗平台

Publications (1)

Publication Number Publication Date
CN119954917A true CN119954917A (zh) 2025-05-09

Family

ID=66819031

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411849786.4A Pending CN119954917A (zh) 2017-12-15 2018-12-17 作为疫苗的修饰的梭菌神经毒素和结合疫苗平台
CN201880081008.1A Active CN111479821B (zh) 2017-12-15 2018-12-17 作为疫苗的修饰的梭菌神经毒素和结合疫苗平台

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880081008.1A Active CN111479821B (zh) 2017-12-15 2018-12-17 作为疫苗的修饰的梭菌神经毒素和结合疫苗平台

Country Status (5)

Country Link
US (2) US11491239B2 (https=)
EP (1) EP3723784A4 (https=)
JP (2) JP7494115B2 (https=)
CN (2) CN119954917A (https=)
WO (1) WO2019118974A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3723784A4 (en) * 2017-12-15 2022-01-12 The Medical College of Wisconsin, Inc. USE OF MODIFIED CLOSTRIDIAL NEUROTOXINS AS VACCINES AND CONJUGATE VACCINE PLATFORMS
WO2020024002A1 (en) * 2018-07-31 2020-02-06 Snoretox Pty Ltd Pegylated tetanus neurotoxins and treatment of hypotonia
US12344635B2 (en) 2020-03-24 2025-07-01 The Medical College Of Wisconsin, Inc. COVID-19 vaccine
BR112022024303A2 (pt) 2020-05-30 2023-01-31 Prime Bio Inc Composição de vacina recombinante oral/sublingual/nasal, candidatos a vacina recombinante, e método de imunização contra a covid-19
WO2022083585A1 (zh) * 2020-10-20 2022-04-28 上海瑞宙生物科技有限公司 一种蛋白多糖结合物及其应用
CN114958887B (zh) * 2021-02-26 2024-10-25 重庆誉颜制药有限公司 一种经修饰的毒素多肽的制备方法
CN115192702B (zh) * 2022-06-22 2025-07-15 上海赛伦生物技术股份有限公司 一种破伤风修饰性mRNA疫苗及其制备方法
CN115304673B (zh) * 2022-06-24 2024-10-01 上海赛伦生物技术股份有限公司 一种马抗破伤风特异性免疫球蛋白F(ab’)2的纯化方法及其应用
WO2026015556A1 (en) * 2024-07-08 2026-01-15 The Medical College Of Wisconsin, Inc. BoNT AND TeNT POLYPEPTIDE FRAGMENTS AND/OR VARIANTS, COMPOSITIONS, POLYNUCLEOTIDES, VACCINES, AND CONJUGATE VACCINE PLATFORMS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1232304C (zh) * 1996-03-23 2005-12-21 财团法人阪大微生物病研究会 破伤风毒素功能性片段抗原和破伤风疫苗
GB9914861D0 (en) 1999-06-25 1999-08-25 Imperial College Tetanus toxin polypeptides
ATE348178T1 (de) * 1999-08-25 2007-01-15 Allergan Inc Aktivierbare rekombinante neurotoxine
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US8853360B2 (en) * 2010-06-23 2014-10-07 Wisconsin Alumni Research Foundation Engineered botulinum neurotoxin C1 with selective substrate specificity
EP3723784A4 (en) * 2017-12-15 2022-01-12 The Medical College of Wisconsin, Inc. USE OF MODIFIED CLOSTRIDIAL NEUROTOXINS AS VACCINES AND CONJUGATE VACCINE PLATFORMS
US12344635B2 (en) 2020-03-24 2025-07-01 The Medical College Of Wisconsin, Inc. COVID-19 vaccine

Also Published As

Publication number Publication date
US20200384120A1 (en) 2020-12-10
CN111479821A (zh) 2020-07-31
US11491239B2 (en) 2022-11-08
JP7494115B2 (ja) 2024-06-03
JP2023123432A (ja) 2023-09-05
WO2019118974A4 (en) 2019-10-31
CN111479821B (zh) 2024-12-31
US20240139332A1 (en) 2024-05-02
JP7797441B2 (ja) 2026-01-13
WO2019118974A2 (en) 2019-06-20
JP2021506824A (ja) 2021-02-22
US12611464B2 (en) 2026-04-28
EP3723784A2 (en) 2020-10-21
WO2019118974A3 (en) 2019-08-15
EP3723784A4 (en) 2022-01-12

Similar Documents

Publication Publication Date Title
CN111479821B (zh) 作为疫苗的修饰的梭菌神经毒素和结合疫苗平台
US8883172B2 (en) Chemically modified peptides with improved immunogenicity
Webb et al. Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3
AU2013211973B2 (en) Vaccines against clostridium difficile comprising recombinant toxins
CN103974718A (zh) 基于艰难梭菌毒素的疫苗
US20130345398A1 (en) Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US7037680B2 (en) Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US20070104737A1 (en) Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US20150273042A1 (en) Pilus proteins and compositions
US7820411B2 (en) Escherichia coli-derived vaccine and therapy against botulism
AU2002228887A1 (en) Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US20100273211A1 (en) Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US20260053936A1 (en) Immunogenic protective antigen conjugates
WO2026015556A1 (en) BoNT AND TeNT POLYPEPTIDE FRAGMENTS AND/OR VARIANTS, COMPOSITIONS, POLYNUCLEOTIDES, VACCINES, AND CONJUGATE VACCINE PLATFORMS
US20060141572A1 (en) Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination